#USA #Cambrex #API Manufacturing #Drug Supply #Charles City, Iowa

Cambrex Strengthens U.S. Drug Supply with Major Investment

Cambrex, a leading global contract development and manufacturing organization (CDMO), has announced a substantial investment of $120 million to enhance its manufacturing capabilities in the United States. This initiative comes at a time when there is an increasingly urgent need for domestic production of active pharmaceutical ingredients (API), driven by a growing demand for drug supply resilience.

Addressing the Need for Local Manufacturing

In a statement made by Cambrex’s CEO, Thomas Loewald, he highlighted that their customers, in conjunction with federal and state agencies, are actively reshoring drug manufacturing to the U.S. As the largest pharmaceutical market in the world, local API production is essential for ensuring supply chain security. Loewald asserts that Cambrex will be at the forefront of this effort, facilitating the strong demand from clients to utilize the expanded manufacturing capacity.

The funds will be allocated towards increasing the large-scale manufacturing capacity at Cambrex's Charles City, Iowa facility by 40%, which will now have a capacity close to one million liters. This facility is known for producing a wide array of APIs and pharmaceutical intermediates, catering to both highly potent molecules and controlled substances.

Commitment to Stability in Pharmaceutical Manufacturing

Loewald emphasized, "With rising demand for U.S.-based supply chains for critical therapies, Cambrex is focused on supporting the long-term stability of pharmaceutical manufacturing in the United States." He reaffirmed the company’s dedication to addressing the evolving needs of clients who require small molecule and peptide manufacturing services.

The new investment not only reflects Cambrex's resolve to enhance operational capabilities but also builds upon its historical trend of investment in drug development and manufacturing networks. In recent years, Cambrex has made several strategic expansions, which include:

• - Adding highly potent API and large-scale manufacturing capabilities in Charles City, Iowa, in 2022.
• - Establishing state-of-the-art laboratories and manufacturing capacity designed for commercial therapies aimed at rare diseases in High Point, North Carolina, in 2023.
• - Expanding capabilities and introducing new GMP manufacturing capacity for peptide therapeutics in Waltham, Massachusetts, in 2025.

These expansions underscore Cambrex's commitment to meeting the pharmaceutical industry's growing demand and adapting to its evolving capabilities.

About Cambrex

With over 40 years of experience in the sector, Cambrex is recognized as a premier global CDMO that provides comprehensive drug substance development and manufacturing through the entire lifecycle of drug production. The organization boasts a workforce of around 2,000 experts serving clients globally, particularly in North America and Europe. The company specializes in various drug substance technologies and capabilities, such as continuous flow processes, controlling substances, peptide synthesis, solid-state science, material characterization, and highly potent APIs.

As Cambrex moves forward with this major investment, the company reinforces its vital role in ensuring a more reliable and resilient U.S. drug supply chain, aiming to meet not just current demands but future challenges as well. With robust manufacturing capabilities, Cambrex is set to be a key player in the pharmaceutical landscape, providing critical support in an industry increasingly focused on local production.